Rexatilux
·
- Prescription status not stated
- Eyes and ears
- Active substance
- Ranibizumab
- Used in
- Eyes and ears
- Made by
- Intas Third Party Sales 2005 S.L.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Rexatilux is indicated in adults for: - The treatment of neovascular (wet) age-related macular degeneration (AMD) - The treatment of visual impairment due to diabetic macular oedema (DME) - The treatment of proliferative diabetic retinopathy (PDR) - The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) - The treatment of visual impairment due to choroidal neovascularisation (CNV).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Intas Third Party Sales 2005 S.L. |
|---|---|
| Active substance | Ranibizumab |
| Used in | Eyes and ears |
| Classification | S01LA04 · Eyes and ears |
| Biosimilar | Yes — a biosimilar medicine, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2026-06-19 |
| Last updated by the regulator | 2026-07-03 |
| EMA product number | EMEA/H/C/006634 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.